Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · IEX Real-Time Price · USD
4.390
-0.110 (-2.44%)
At close: Jul 19, 2024, 4:00 PM
4.380
-0.010 (-0.23%)
Pre-market: Jul 22, 2024, 7:27 AM EDT
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd.
Country | Israel |
Founded | 2003 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | Amir Reichman M.B.A., M.Sc. |
Contact Details
Address: Jerusalem Biopark, 2nd Floor, Hadassah Ein Kerem Campus Jerusalem, L3 00000 Israel | |
Phone | 972-8-9302529 |
Website | scinai.com |
Stock Details
Ticker Symbol | SCNI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | ILS |
CIK Code | 0001611747 |
ISIN Number | US09073Q2049 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
Dr. Tamar Ben-Yedidia Ph.D. | Chief Science Officer |
Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
Dalit Weinstein Fischer | Chief Technology Officer |
Joshua E. Phillipson B.Sc., M.B.A. | Director of Communications and Investor Relations |
Liat Halpert | Head of Business Development and Sales |
Moran Ahdout Fruchter L.L.B. | Chief of Staff |
Merav Kamensky | Head of Quality Control |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 15, 2024 | 6-K | Report of foreign issuer |
Jul 15, 2024 | 6-K | Report of foreign issuer |
Jul 8, 2024 | 6-K | Report of foreign issuer |
Jul 8, 2024 | 6-K | Report of foreign issuer |
Jul 8, 2024 | 6-K | Report of foreign issuer |
Jun 14, 2024 | 6-K | Report of foreign issuer |
Jun 13, 2024 | 6-K | Report of foreign issuer |
Jun 13, 2024 | 6-K | Report of foreign issuer |
May 28, 2024 | 6-K | Report of foreign issuer |
May 16, 2024 | 424B3 | Prospectus |